Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Lowers Price Target to $140
Morgan Stanley analyst Michael Ulz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Equal-Weight and lowers the price target from $150 to $140.
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna’s Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours.
FDA Accepts Mirati Therapeutics’ New Drug Appliaction For Adagrasib As Treatment Of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA)
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows.